← All organizations
Highest phase reached
Phase 4
First clinical trial
Mar 1, 2004First marketed drug
Apr 12, 2010First NDA
Apr 27, 2012Last known activity
Jan 25, 2022
Defunct as of Jul 7, 2020
Timeline
1990s
- Jan 1, 1991
Vivus— Founded
2010s
- Apr 12, 2010
pancrelipase— NDA Secondary Org
- Apr 27, 2012
avanafil— NDA Organization
- Jul 17, 2012
phentermine— Marketing Organization
2020s
- Jul 7, 2020
Vivus— Defunct
Drugs by trial phase (25 distinct, 43 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Alzheimer Disease
- Apnea
- Cachexia
- Diabetes Mellitus, Type 2
- Erectile Dysfunction
- Exocrine Pancreatic Insufficiency
- Liver Diseases
- Obesity
- Overweight
- Pediatric Obesity
- Renal Insufficiency
- Sexual Dysfunction, Physiological
- Sexual Dysfunctions, Psychological
- Sleep Apnea, Obstructive
- Sleep Apnea Syndromes
- Torsades de Pointes
Marketed drugs (6)
Recent trials (50)
- NCT05215418Lead sponsorPhase 4Jan 25, 2022
- NCT04098237CollaboratorPhase 2Dec 17, 2020
- NCT03922945Lead sponsorPhase 4Apr 22, 2019
- NCT02714062Lead sponsorPhase 4Mar 1, 2016
- NCT02301416CollaboratorN/ADec 1, 2014
- NCT02229214Lead sponsorPhase 4Aug 1, 2014
- NCT02033200Lead sponsorPhase 4Jan 1, 2014
- NCT01768676Lead sponsorPhase 4Dec 1, 2012
- NCT01698684Study directorPhase 4Sep 1, 2012
- NCT01698684Lead sponsorPhase 4Sep 1, 2012
- NCT01428362Lead sponsorPhase 2Aug 1, 2011
- NCT01095601Study directorPhase 1Apr 1, 2010
- NCT01415128Study directorPhase 1Apr 1, 2010
- NCT01095588Study directorPhase 1Apr 1, 2010
- NCT01095588Lead sponsorPhase 1Apr 1, 2010
Details
- Founded
- Mountain View, CA, US Jan 1, 1991
- First NDA
- Apr 27, 2012
- Last known activity
- Jan 25, 2022